Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 IL-10/IL15 CAR-NK in Refractory/Relapsed Autoimmune Diseases
NCT06614270Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of anti-cd19 interleukin-10 + interleukin-15 chimeric antigen receptor natural killer cells in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and 3 more, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 12 months. Started Jan 2025; status: recruiting.
02
Drugs
anti-cd19 interleukin-10 + interleukin-15 chimeric antigen receptor natural killer cells
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)Sjogren's syndrome
Beyond the preview
Go deeper on NCT06614270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06614270.